# Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

> **NCT07344220** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Hoag Memorial Hospital Presbyterian** · enrollment: 39 (estimated)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg

## Key facts

- **NCT ID:** NCT07344220
- **Lead sponsor:** Hoag Memorial Hospital Presbyterian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-01
- **Primary completion:** 2028-11
- **Final completion:** 2029-04
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344220, "Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07344220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*